Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHORT: Short vs Extended Carbapenem for Febrile Neutropenia
NCT02149329Phase 4Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Dec 2014
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of imipenem + cilastatin and meropenem in febrile neutropenia (FN) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Percentage of patients with failed treatment and Death, ARDS, or Septic shock. Started Dec 2014; status: completed.
02
Drugs
imipenem + cilastatinmeropenem
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT02149329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02149329.